Published in FASEB J on August 19, 2004
The relevance of animal models in multiple sclerosis research. Pathophysiology (2011) 1.40
Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol J (2009) 1.15
Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol (2009) 1.00
Magnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals. NeuroRx (2005) 0.97
MRI in rodent models of brain disorders. Neurotherapeutics (2011) 0.94
Myelin repair: the role of stem and precursor cells in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci (2008) 0.93
Invited article: human natural autoantibodies in the treatment of neurologic disease. Neurology (2009) 0.93
Promoting remyelination in multiple sclerosis-recent advances. Drugs (2013) 0.91
PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation. PLoS One (2013) 0.88
Method of identifying natural antibodies for remyelination. J Clin Immunol (2010) 0.85
Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies. Arch Neurol (2009) 0.85
Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult Scler (2009) 0.84
Magnetic resonance imaging at 1.5 T with immunospecific contrast agent in vitro and in vivo in a xenotransplant model. MAGMA (2006) 0.84
A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. Dis Model Mech (2015) 0.82
Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci (2013) 0.81
High-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance. Anal Chem (2012) 0.81
Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire. Expert Rev Neurother (2013) 0.81
IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp Brain Res (2006) 0.80
In vivo mouse spinal cord imaging using echo-planar imaging at 11.75 T. MAGMA (2007) 0.80
Remyelination Therapy in Multiple Sclerosis. Front Neurol (2015) 0.79
Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis. Neurol Res Int (2011) 0.78
Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther (2016) 0.78
Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease. Mol Neurobiol (2015) 0.77
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord (2015) 0.76
Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis. Int J Phys Med Rehabil (2016) 0.75
Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc (2007) 6.11
The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol (2011) 5.41
Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol (2007) 4.66
Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol (2004) 2.84
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol (2007) 2.53
Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. Arch Neurol (2004) 2.37
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol (2010) 1.91
Hip arthroplasty. Lancet (2012) 1.73
Retracted Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol (2008) 1.69
Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Statistical SPECT processing in MRI-negative epilepsy surgery. Neurology (2014) 1.46
Retracted CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection. Cancer Res (2009) 1.41
Revision total hip arthroplasty in Jehovah's Witnesses. Orthopedics (2012) 1.40
The relevance of animal models in multiple sclerosis research. Pathophysiology (2011) 1.40
Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelination in experimental autoimmune encephalitis. J Clin Invest (2009) 1.38
Induction of blood brain barrier tight junction protein alterations by CD8 T cells. PLoS One (2008) 1.38
Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol (2004) 1.36
Differential effect of IL-27 on developing versus committed Th17 cells. J Immunol (2009) 1.34
Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol (2010) 1.30
Survival of hard-on-hard bearings in total hip arthroplasty: a systematic review. Clin Orthop Relat Res (2011) 1.28
Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis (2006) 1.26
Retracted Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res (2004) 1.26
Asthma-related environmental fungus, Alternaria, activates dendritic cells and produces potent Th2 adjuvant activity. J Immunol (2009) 1.26
Clearance of Theiler's virus infection depends on the ability to generate a CD8+ T cell response against a single immunodominant viral peptide. Eur J Immunol (2003) 1.25
Lineage(-)Sca1+c-Kit(-)CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J Immunol (2011) 1.22
IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett (2008) 1.21
Retracted Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. J Immunol (2003) 1.21
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain (2010) 1.19
CD8 T cell-initiated vascular endothelial growth factor expression promotes central nervous system vascular permeability under neuroinflammatory conditions. J Immunol (2009) 1.17
Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci (2013) 1.17
Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol J (2009) 1.15
Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 8(5):528-535 (November 1990). Biotechniques (2013) 1.15
A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res (2007) 1.15
Retracted Dendritic cells activated by cross-linking B7-DC (PD-L2) block inflammatory airway disease. J Allergy Clin Immunol (2005) 1.15
Interleukin-6 protects anterior horn neurons from lethal virus-induced injury. J Neurosci (2003) 1.15
Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs (2009) 1.14
Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci (2003) 1.14
Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflammation (2009) 1.13
CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes. Mol Ther (2012) 1.12
CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination. J Neuroimmunol (2007) 1.12
Efficient central nervous system remyelination requires T cells. Ann Neurol (2003) 1.11
The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol Res (2006) 1.11
Antigen-specific CD8+ T cells mediate a peptide-induced fatal syndrome. J Immunol (2005) 1.09
Retracted Blockade of allergic airway inflammation following systemic treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody. J Immunol (2004) 1.09
Reduced dislocation rates and excellent functional outcomes with large-diameter femoral heads. J Arthroplasty (2013) 1.08
Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol (2004) 1.08
Advance pre-operative chlorhexidine reduces the incidence of surgical site infections in knee arthroplasty. Int Orthop (2010) 1.08
Acute hemorrhagic demyelination in a murine model of multiple sclerosis. J Neuroinflammation (2008) 1.07
Retracted B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. Proc Natl Acad Sci U S A (2005) 1.07
Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest (2002) 1.07
Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis. J Neuropathol Exp Neurol (2009) 1.06
Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia (2002) 1.06
Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem (2008) 1.06
Prophylactic oral antibiotics reduce reinfection rates following two-stage revision total knee arthroplasty. Int Orthop (2010) 1.05
HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. J Neuroimmunol (2005) 1.04
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA class II-transgenic mice. Eur J Immunol (2004) 1.04
Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J (2002) 1.04
Disrupted spatial memory is a consequence of picornavirus infection. Neurobiol Dis (2006) 1.04